Glutamine Test

Your body's most abundant free amino acid does not usually make it onto a standard blood panel, yet it shifts meaningfully when you are under metabolic stress, fighting severe infection, or dealing with serious illness. In large studies of hospitalized adults, both unusually low and unusually high levels have tracked with worse outcomes, making this one of the more informative readouts of whole-body stress biology.

For someone focused on prevention, this test is less a screening tool and more a research-grade snapshot of how your amino acid balance is holding up. It is a supporting piece of a broader metabolic picture, not a stand-alone answer to any one question.

What This Molecule Actually Does

Glutamine is classified as a conditionally essential amino acid, meaning your body usually makes enough, but demand can outpace supply during illness, major surgery, or heavy training. Skeletal muscle is the primary site of production, while the small intestine, kidneys, and immune cells are heavy consumers.

It acts as a nitrogen shuttle, a fuel for rapidly dividing cells, and a building block for the body's main internal antioxidant (glutathione). In the brain, it is part of the cycle that recycles the main excitatory and calming neurotransmitters between neurons and support cells (astrocytes).

Why Levels Matter in Critical Illness and Sepsis

In the intensive care setting, the glutamine pool behaves like a stress gauge. Both ends of the spectrum carry risk, which is why a single number has to be interpreted in context rather than on a simple "higher is better" scale.

In a study of 469 internal medicine patients admitted with sepsis, those with progressively higher plasma glutamine had deeper drops in lymphocytes, more severe metabolic disturbance, and higher 30-day and 6-month mortality. A separate ICU study of 269 critically ill adults found that a high level at admission (hyperglutaminemia) was an independent predictor of higher 6-month mortality, often tied to acute liver dysfunction.

Low levels carry their own signal. In a cohort of 330 ICU patients, low plasma glutamine correlated with higher illness severity scores (APACHE II and SOFA, standard ICU scoring systems that rate how sick someone is). The clinical framing that makes both findings consistent: this is not a "good number, bad number" marker. It is a phenotype indicator. Low values often signal catabolic stress (a breakdown state where the body consumes its own tissues for fuel) and heavy consumption by immune and gut cells, while high values often signal impaired clearance by a damaged liver. Different phenotypes, different risks.

Cardiovascular Disease

The cardiovascular data are more straightforward. Across six cohorts pooling 7,897 people with 1,373 heart attacks, each standard-deviation increase in circulating glutamine was associated with about 26% lower risk of a future heart attack (hazard ratio 0.74, 95% CI 0.67 to 0.82), and the association held up after controlling for traditional risk factors.

In the PREDIMED study of Mediterranean adults at high cardiovascular risk, a higher ratio of glutamine to glutamate was linked to lower risk of new heart failure (odds ratio 0.80 per standard deviation, 95% CI 0.67 to 0.94), again surviving adjustment for smoking, blood pressure, diabetes, and lipids. No meaningful link was seen for atrial fibrillation.

Cancer Risk and Prognosis

In a nested case-control analysis within the EPIC cohort comparing 654 colorectal cancer cases to 654 controls, people in the highest quartile had about 35% lower odds of developing colorectal cancer compared with the lowest quartile (odds ratio 0.65, 95% CI 0.46 to 0.92). The UK Biobank analysis of 111,323 people with 1,221 incident cases showed a weaker, borderline inverse trend.

Once cancer is present, the picture can flip. In a study of 123 colorectal cancer patients, lower pretreatment serum glutamine was independently linked to more advanced stage, lymph node involvement, and shorter overall and disease-free survival. In metastatic castration-resistant prostate cancer (75 men on taxane chemotherapy), higher plasma glutamine was tied to worse PSA response and shorter survival.

The reconciliation: circulating glutamine is not a simple "cancer risk" number. In healthy populations, higher levels may reflect well-regulated metabolism. In people already living with a tumor, the picture depends on how aggressively the tumor is pulling glutamine from the host, and sometimes on the tumor's own glutamine demand. This is why a single reading outside the context of your broader health story is hard to interpret.

Brain, Mood, and Neurodegeneration

Glutamine sits at the heart of neurotransmitter cycling in the brain. A meta-analysis of brain imaging studies in major depressive disorder found decreased levels of the combined glutamate-plus-glutamine signal in the medial frontal cortex of people with depression. A Mendelian randomization study, which uses genetic variants to probe whether a relationship is causal, suggested that lower circulating glutamine causally increases the risk of major depressive disorder and depressive symptoms, and that higher BMI lowers glutamine while raising depression risk.

In medication-free patients with major depressive disorder, plasma glutamine and the glutamine-to-glutamate ratio were abnormal at baseline and normalized after 8 weeks of antidepressant treatment. In cerebrospinal fluid from people with probable Alzheimer's disease and depression, glutamate and glutamine were both elevated.

Reference Ranges

There are no standardized clinical reference intervals for plasma glutamine published by major guideline bodies, and assays differ across labs. The numbers below come from critical care observational research in ICU adults. They are illustrative orientation for how researchers classify levels, not universal targets for healthy adults. Your lab will likely report different cutpoints, possibly in different units.

Source: ICU observational data from Smedberg et al. (2021) and Mearelli et al. (2025). Compare your results within the same lab over time for the most meaningful trend. A single number in isolation, especially outside a critical care context, should not be treated as diagnostic.

Tracking Your Trend

Because this is a research-grade marker without consensus cutpoints, tracking your own trajectory is far more useful than comparing any single reading to a population average. A baseline value tells you where you are today. A repeat value in 3 to 6 months, especially if you have started an intervention that could plausibly affect amino acid balance (sustained dietary change, recovery from illness, new chronic medication), tells you whether something is actually moving.

Annual retesting is a reasonable floor for someone actively managing their health. Because levels can shift meaningfully with acute illness, recent intense exercise, and hospital-level stress, try to test under similar baseline conditions each time: similar fasting status, no recent acute illness, and not in the hours after a hard workout.

When Results Can Be Misleading

Several factors can distort a single reading. Knowing them prevents you from over-interpreting a one-off number.

• Acute illness or major surgery: severe sepsis, trauma, and burns can drive levels well outside your personal baseline in either direction for days to weeks.
• Strenuous exercise: prolonged or heavy training bouts are associated with decreased plasma levels, and intense cycling has been shown to transiently raise the combined brain glutamate-plus-glutamine signal by about 29% before normalizing within 30 minutes.
• Certain medications: the chemotherapy drug asparaginase drops plasma levels to roughly 5% of baseline within an hour by design, and valproic acid is associated with lower glutamine and higher glutamate in children with drug-related liver injury. A reading taken while on these drugs will not reflect your underlying biology.
• Sample handling: the glutamate-to-glutamine ratio has been shown to change with suboptimal sample storage, so proper lab handling matters more here than for many routine tests.

Decision Pathway for Abnormal Results

If your result lands outside the intermediate range, the first step is to repeat the test under clean conditions (no recent acute illness, no heavy training in the preceding 24 to 48 hours). If the pattern persists, the right next step depends on the direction and your clinical context.

A persistently low value alongside signs of catabolic stress (unintended weight loss, chronic inflammation on hs-CRP, low albumin, frequent infections) is worth investigating with a clinician experienced in nutrition and metabolism. A persistently high value alongside abnormal liver enzymes (ALT, AST, GGT) warrants a liver-focused workup, since impaired hepatic clearance is one of the main drivers of elevated levels. In both cases, this test is a supporting data point, not a diagnosis on its own.